NGNE
Neurogene Inc.
NASDAQ · USHealthcareBiotechnology
$36.84-1.27%
Price as of Jul 20, 2026
NGNE ownership
Neurogene Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
6
Net (3m)
-$484.3K
Insider trades by month Buys Sells
Nov
Mar
May
Mar
May
Jul
Context3-month price +34.5%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine Mikaildirector, officer: President and CFO | Sell | 600 | $36.02 |
| Jul 7, 2026 | Cvijic Christine Mikaildirector, officer: President and CFO | Sell | 4,200 | $36.13 |
| Jul 2, 2026 | Cvijic Christine Mikaildirector, officer: President and CFO | Sell | 739 | $34.06 |
| Jul 2, 2026 | Cvijic Christine Mikaildirector, officer: President and CFO | Sell | 2,531 | $34.58 |
| Jul 2, 2026 | Cvijic Christine Mikaildirector, officer: President and CFO | Sell | 1,530 | $35.23 |
| Jun 16, 2026 | Woods Keithdirector | Grant | 7,700 | $42.59 |
| Jun 16, 2026 | Woods Keithdirector | Grant | 15,400 | $32.30 |
| Jun 16, 2026 | Woods Keithdirector | Grant | 12,050 | $20.40 |
| May 8, 2026 | Cvijic Christine Mikaildirector, officer: President and CFO | Sell | 4,800 | $30.07 |
| May 7, 2026 | Shafer Christinaofficer: Chief Commercial Officer | Grant | 120,000 | $28.94 |
| Mar 30, 2026 | Cvijic Christine Mikailofficer: President and CFO | Sell | 2,558 | $21.62 |
| Mar 30, 2026 | McMinn Racheldirector, officer: Chief Executive Officer | Sell | 3,352 | $22.07 |
| Mar 30, 2026 | Jordan Julieofficer: Chief Medical Officer | Sell | 828 | $21.89 |
| Mar 17, 2026 | Cvijic Christine Mikailofficer: President and CFO | Sell | 1,395 | $21.25 |
| Mar 17, 2026 | Cvijic Christine Mikailofficer: President and CFO | Sell | 263 | $22.02 |
| Mar 17, 2026 | Cobb Stuartofficer: Chief Scientific Officer | Sell | 3,991 | $20.41 |
| Mar 17, 2026 | Cobb Stuartofficer: Chief Scientific Officer | Sell | 2,658 | $21.34 |
| Mar 17, 2026 | Cobb Stuartofficer: Chief Scientific Officer | Sell | 148 | $22.08 |
| Mar 17, 2026 | Cvijic Christine Mikailofficer: President and CFO | Sell | 2,387 | $20.42 |
| Mar 3, 2026 | Cvijic Christine Mikailofficer: President and CFO | Sell | 4,800 | $25.11 |
| Feb 24, 2026 | BAFFI ROBERTdirector | Grant | 12,050 | $17.64 |
| Feb 24, 2026 | Cobb Stuartofficer: Chief Scientific Officer | Grant | 16,500 | — |
| Feb 24, 2026 | Jordan Julieofficer: Chief Medical Officer | Grant | 4,900 | — |
| Feb 24, 2026 | Jordan Julieofficer: Chief Medical Officer | Grant | 29,600 | $17.64 |
| Feb 24, 2026 | Cvijic Christine Mikailofficer: President and CFO | Grant | 22,000 | — |
| Feb 24, 2026 | Cvijic Christine Mikailofficer: President and CFO | Grant | 131,900 | $17.64 |
| Feb 24, 2026 | McMinn Racheldirector, officer: Chief Executive Officer | Grant | 25,900 | — |
| Feb 24, 2026 | McMinn Racheldirector, officer: Chief Executive Officer | Grant | 155,100 | $17.64 |
| Feb 24, 2026 | Woods Keithdirector | Grant | 12,050 | $17.64 |
| Feb 24, 2026 | Freedland Cory S.director | Grant | 12,050 | $17.64 |
Source: NGNE SEC Form 4 filings, latest Jul 7, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their NGNE positions over the last 6 months (SEC Form 13F).
Increased
69
New positions
34
Reduced
46
Sold out
24
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | Unchanged | 1.7M | May 15, 2026 |
| SAMSARA BIOCAPITAL, LLC | Unchanged | 1.7M | Feb 17, 2026 |
| REDMILE GROUP, LLC | Increased | 1.5M | Feb 17, 2026 |
| REDMILE GROUP, LLC | Unchanged | 1.5M | May 15, 2026 |
| CASDIN CAPITAL, LLC | Increased | 1.4M | May 15, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 1.4M | May 15, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 1.4M | Feb 17, 2026 |
| CASDIN CAPITAL, LLC | Unchanged | 1.3M | Feb 17, 2026 |
| ECOR1 CAPITAL, LLC | Unchanged | 1.3M | Feb 17, 2026 |
| ECOR1 CAPITAL, LLC | Unchanged | 1.3M | May 15, 2026 |
| BLACKROCK, INC. | Increased | 1.0M | May 13, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 992K | May 15, 2026 |
| BAKER BROS. ADVISORS LP | Unchanged | 992K | Feb 17, 2026 |
| BLACKROCK, INC. | Reduced | 946K | Feb 12, 2026 |
| Trails Edge Capital Partners, LP | New Position | 785K | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.